Angiotensin converting enzyme inhibition does not affect the response to exogenous angiotensin II in the human forearm.
Suppression of endogenous levels of angiotensin II by angiotensin converting enzyme inhibition, may result in up-regulation of vascular AT1 receptors. We have evaluated the effects of orally administered enalapril on angiotensin II induced vasoconstriction in the human forearm. Subjects received in random order, enalapril (20 mg) or matched placebo daily for 2 weeks. Forearm blood flow response to increasing doses of angiotensin II was measured using venous occlusion plethysmography at the beginning of the study and at the end of each 2 week treatment period. Treatment with enalapril significantly reduced plasma angiotensin II levels and supine blood pressure compared with placebo. The percentage reductions in forearm blood flow in the infused arm, in response to the maximum dose of angiotensin II (50,000 fmol min-1) were 48.1 +/- 3.6% at baseline, 57.5 +/- 3.6% on placebo and 54.5 +/- 4.2% on enalapril. The differences were not significantly different. This demonstrates that suppression of plasma angiotensin II for a 14 day period does not enhance the response to exogenous intra-arterial angiotensin II in the human forearm of healthy salt replete subjects.
Lyons
D
D
Department of Medicine and Therapeutics, University of Aberdeen.
Stewart
D
D
Webster
J
J
Benjamin
N
N
D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D000804:Angiotensin II / Q000037:antagonists & inhibitors* / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004656:Enalapril / Q000008:administration & dosage / Q000494:pharmacology*; D005542:Forearm; D006801:Humans; D010991:Plethysmography; D015854:Up-Regulation; D014661:Vasoconstriction / Q000187:drug effects*; D044465:White People
D000804:Angiotensin II; D004656:Enalapril